Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases

Seung Yong Park, Yasmin Hisham, Hyun Mu Shin, Su Cheong Yeom, Soohyun Kim

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Natural soluble antagonist and decoy receptor on the surface of the cell membrane are evolving as crucial immune system regulators as these molecules are capable of recognizing, binding, and neutralizing (so-called inhibitors) their targeted ligands. Eventually, these soluble antagonists and decoy receptors terminate signaling by prohibiting ligands from connecting to their receptors on the surface of cell membrane. Interleukin-18 binding protein (IL-18BP) participates in regulating both Th1 and Th2 cytokines. IL-18BP is a soluble neutralizing protein belonging to the immunoglobulin (Ig) superfamily as it harbors a single Ig domain. The Ig domain is essential for its binding to the IL-18 ligand and holds partial homology to the IL-1 receptor 2 (IL-1R2) known as a decoy receptor of IL-1α and IL-1β. IL-18BP was defined as a unique soluble IL-18BP that is distinct from IL-18Rα and IL-18Rβ chain. IL-18BP is encoded by a separated gene, contains 8 exons, and is located at chr.11 q13.4 within the human genome. In this review, we address the difference in the biological activity of IL-18BP isoforms, in the immunity balancing Th1 and Th2 immune response, its critical role in autoimmune diseases, as well as current clinical trials of recombinant IL-18BP (rIL-18BP) or equivalent.

Original languageEnglish
Article number1750
Issue number7
StatePublished - Jul 2022
Externally publishedYes


  • IL-18BP
  • Th1/Th2 balance
  • autoimmune diseases
  • clinical trials
  • soluble anti-IL-18


Dive into the research topics of 'Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases'. Together they form a unique fingerprint.

Cite this